• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»antibody engineering

What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering

By Soujanya Ravi on April 28, 2026   Pharma & Biotech  

What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering

Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.

MindWalk adds VHH capability as nanobodies gain ground in CAR-T and multispecific design

By Pallavi Madhiraju on March 7, 2026   Pharma & Biotech  

MindWalk adds VHH capability as nanobodies gain ground in CAR-T and multispecific design

MindWalk launches B Cell Llama, a VHH nanobody platform for bispecific drug design. Peer-reviewed data raises key questions about function, immunogenicity, and AI.

Recent Posts

  • Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
  • Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes